Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

441
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
441
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

144
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
144

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcium Signaling Modulator 4-MPTC Reduces Proliferative and Migration Activities of MDA-MB-468 Breast Cancer Cells.

Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections·2026
Same author

A series of conjugates based on prostate-specific membrane antigen ligands with the chelating agent DOTA: synthesis, radiolabeling, and biological activity.

European journal of medicinal chemistry·2025
Same author

Test System for Studying Biotin Transport upon SLC5A6 Gene Inactivation.

Acta naturae·2025
Same author

Protein Complementation Approach for Quantitative and Qualitative Analysis of hTERP in Cell.

Doklady. Biochemistry and biophysics·2025
Same author

Anti-inflammatory action of new hybrid <i>N</i>-acyl-[1,2]dithiolo-[3,4-<i>c</i>]quinoline-1-thione.

SAR and QSAR in environmental research·2024
Same author

PRPF19 mRNA Encodes a Small Open Reading Frame That Is Important for Viability of Human Cells.

Doklady. Biochemistry and biophysics·2024

Related Experiment Video

Updated: May 17, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K

New Kinase Inhibitors That Are Selectively Cytotoxic for Tumor Cells.

D A Skvortsov1, I V Zhirkina2, D A Ipatova2

  • 1Chemistry Department and Belozersky Institute of Physico-Chemical Biology, Moscow State University, Moscow, Russia. skvorratd@mail.ru.

Doklady. Biochemistry and Biophysics
|April 11, 2025
PubMed
Summary

Researchers identified new multikinase inhibitors, STOCK7S-36520 and STOCK7S-47016, that selectively target tumor cells. These compounds show promise for cancer therapy by inhibiting specific kinases like GCK.

Keywords:
FCCT testanticancer drugscytotoxicitykinase inhibitorsselectivity

More Related Videos

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

10.8K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

7.8K

Related Experiment Videos

Last Updated: May 17, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

10.8K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

7.8K

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Developing targeted cancer therapies requires identifying compounds with selective cytotoxicity against tumor cells.
  • Phenotypic screening in cocultures offers a method to discover such selective agents.

Purpose of the Study:

  • To identify novel compounds with selective activity against tumor cells using phenotypic screening.
  • To characterize the mechanism of action of identified compounds as kinase inhibitors.

Main Methods:

  • Phenotypic screening of compounds in cocultures of tumor and non-tumor cell lines (MCF7/MCF10A).
  • Structural analysis of active compounds to identify characteristic motifs.
  • Assay of kinase inhibition activity for identified compounds.
  • Determination of selectivity index across different cell lines (PC3 vs. VA13).

Main Results:

  • Compound STOCK7S-36520 demonstrated selective cytotoxicity in a breast tumor cell coculture.
  • STOCK7S-36520 and its derivative STOCK7S-47016 were identified as novel multikinase inhibitors.
  • STOCK7S-47016 achieved 84% inhibition against GCK kinase.
  • STOCK7S-36520 exhibited a 29-fold selectivity index against prostate tumor cells (PC3) compared to fibroblasts (VA13).

Conclusions:

  • Novel multikinase inhibitors, STOCK7S-36520 and STOCK7S-47016, have been discovered.
  • These compounds display selective cytotoxicity against tumor cells, indicating potential therapeutic applications.
  • The identified inhibitors target specific kinases, offering a basis for further drug development in oncology.